{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:42:09Z","timestamp":1761709329348},"reference-count":39,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1620\/tjem.241.281","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T02:46:10Z","timestamp":1491446770000},"page":"281-286","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma"],"prefix":"10.1620","volume":"241","author":[{"given":"Guoyan","family":"Qi","sequence":"first","affiliation":[{"name":"Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Dong","sequence":"additional","affiliation":[{"name":"Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Gu","sequence":"additional","affiliation":[{"name":"Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Yang","sequence":"additional","affiliation":[{"name":"Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinping","family":"Xue","sequence":"additional","affiliation":[{"name":"Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Albany, C. &amp; Sonpavde, G. (2015) Docetaxel for the treatment of bladder cancer. <i>Expert Opin. Investig. Drugs<\/i>, 24, 1657-1664.","DOI":"10.1517\/13543784.2015.1109626"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bear, H.D., Anderson, S., Brown, A., Smith, R., Mamounas, E.P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D.L. &amp; Wolmark, N.; National Surgical Adjuvant Breast and Bowel Project Protocol B-27 (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. <i>J. Clin. Oncol.<\/i>, 21, 4165-4174.","DOI":"10.1200\/JCO.2003.12.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Betticher, D.C., Has Schmitz, S.F., T\u00f6tsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R.A., Pless, M., Habicht, J., Roth, A.D., Spiliopoulos, A., Stahel, R., Weder, W., Stupp, R. &amp; Egli, F. (2003) Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. <i>J. Clin. Oncol.<\/i>, 21, 1752-1759.","DOI":"10.1200\/JCO.2003.11.040"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bott, M.J., Wang, H., Travis, W., Riely, G.J., Bains, M., Downey, R., Rusch, V. &amp; Huang, J. (2011) Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. <i>Ann. Thorac. Surg.<\/i>, 92, 1984-1992.","DOI":"10.1016\/j.athoracsur.2011.07.078"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Brain, E.G., Bachelot, T., Serin, D., Kirscher, S., Graic, Y., Eymard, J.C., Extra, J.M., Combe, M., Fourme, E., Nogu\u00e8s, C. &amp; Rou\u00ebss\u00e9, J.; RAPP-01 Trial Investigators (2005) Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. <i>JAMA<\/i>, 293, 2367-2371.","DOI":"10.1001\/jama.293.19.2367"},{"key":"6","doi-asserted-by":"crossref","unstructured":"De Santis, M., Lucchese, A., De Carolis, S., Ferrazzani, S. &amp; Caruso, A. (2000) Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. <i>Eur. J. Cancer Care<\/i> (<i>Engl<\/i>), 9, 235-237.","DOI":"10.1046\/j.1365-2354.2000.00231.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Engels, E.A. (2010) Epidemiology of thymoma and associated malignancies. <i>J. Thorac. Oncol.<\/i>, 5, S260-S265.","DOI":"10.1097\/JTO.0b013e3181f1f62d"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Fujii, Y. (2013) The thymus, thymoma and myasthenia gravis. <i>Surg. Today<\/i>, 43, 461-466.","DOI":"10.1007\/s00595-012-0318-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Gandara, D.R., Vokes, E., Green, M., Bonomi, P., Devore, R., Comis, R., Carbone, D., Karp, D. &amp; Belani, C. (2000) Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. <i>J. Clin. Oncol.<\/i>, 18, 131-135.","DOI":"10.1200\/JCO.2000.18.1.131"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Giaccone, G. (2005) Treatment of malignant thymoma. <i>Curr. Opin. Oncol.<\/i>, 17, 140-146.","DOI":"10.1097\/01.cco.0000152628.43867.8e"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Hayashi, M., Manabe, K., Takaoka, T., Yamada, I., Kida, K., Matsuda, H. &amp; Yoshinaga, J. (1995) Long-term change of anti-acetylcholine receptor antibody in patients with myasthenia gravis after thymectomy. <i>Pediatr. Int.<\/i>, 37, 362-366.","DOI":"10.1111\/j.1442-200X.1995.tb03331.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Hernandez-Ilizaliturri, F.J., Tan, D., Cipolla, D., Connolly, G., Debb, G. &amp; Ramnath, N. (2004) Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. <i>Am. J. Clin. Oncol.<\/i>, 27, 68-72.","DOI":"10.1097\/01.coc.0000046301.83671.09"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Hishida, T., Nomura, S., Yano, M., Asamura, H., Yamashita, M., Ohde, Y., Kondo, K., Date, H., Okumura, M. &amp; Nagai, K. (2016) Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. <i>Eur. J. Cardiothorac. Surg.<\/i>, 49, 835-841.","DOI":"10.1093\/ejcts\/ezv239"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Huang, J., Rizk, N.P., Travis, W.D., Riely, G.J., Park, B.J., Bains, M.S., Dycoco, J., Flores, R.M., Downey, R.J. &amp; Rusch, V.W. (2009) Comparison of patterns of relapse in thymic carcinoma and thymoma. <i>J. Thorac. Cardiovasc. Surg.<\/i>, 138, 26-31.","DOI":"10.1016\/j.jtcvs.2009.03.033"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Kim, E.S., Putnam, J.B., Komaki, R., Walsh, G.L., Ro, J.Y., Shin, H.J., Truong, M., Moon, H., Swisher, S.G., Fossella, F.V., Cheri, F.R., Hong, W.K. &amp; Shin, D.M. (2004) Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. <i>Lung Cancer<\/i>, 44, 369-379.","DOI":"10.1016\/j.lungcan.2003.12.010"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Lamarca, A., Moreno, V. &amp; Feliu, J. (2013) Thymoma and thymic carcinoma in the target therapies era. <i>Cancer Treat. Rev.<\/i>, 39, 413-420.","DOI":"10.1016\/j.ctrv.2012.11.005"},{"key":"17","unstructured":"Li, J.l., Zhang, X.R., Liu, J.W., Chen, Z.Y., Lin, Y.C., Wang, Y.D., Chen, Q., Nan, K.J., Song, S.P., Han, F.C., Zhu, Y.Z., Li, L.Y., Zheng, Y.H. &amp; Chu, D.T. (2006) Phase I\/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer. <i>Zhonghua Zhong Liu Za Zhi<\/i>, 28, 309-312."},{"key":"18","doi-asserted-by":"crossref","unstructured":"Li, Z.Y. (2016) China guidelines for the diagnosis and treatment of myasthenia gravis. <i>Neuroimmunol. Neuroinflamm.<\/i>, 3, 1-9.","DOI":"10.20517\/2347-8659.2015.60"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Liu, G.C., Gao, B.L., Yang, H.Q., Qi, G.Y. &amp; Liu, P. (2014) The clinical absolute and relative scoring system-a quantitative scale measuring myasthenia gravis severity and outcome used in the traditional Chinese medicine. <i>Complement. Ther. Med.<\/i>, 22, 877-886.","DOI":"10.1016\/j.ctim.2014.08.003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Makimoto, G., Fujiwara, K., Watanabe, H., Kameyama, N., Matsushita, M., Rai, K., Sato, K., Yonei, T., Sato, T. &amp; Shibayama, T. (2014) nab-Paclitaxel in combination with carboplatin for a previously treated thymic carcinoma. <i>Case Rep. Oncol.<\/i>, 7, 14-17.","DOI":"10.1159\/000357938"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Marx, A., Porubsky, S., Belharazem, D., Saruhan-Direskeneli, G., Schalke, B., Str\u00f6bel, P. &amp; Weis, C.A. (2015) Thymoma related myasthenia gravis in humans and potential animal models. <i>Exp. Neurol.<\/i>, 270, 55-65.","DOI":"10.1016\/j.expneurol.2015.02.010"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Masaoka, A., Monden, Y., Nakahara, K. &amp; Tanioka, T. (1981) Follow-up study of thymomas with special reference to their clinical stages. <i>Cancer<\/i>, 48, 2485-2492.","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Sami, K., Katakana, N., Takada, M., Yoshioka, H. &amp; Shibata, K. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. <i>Lancet Oncol.<\/i>, 11, 121-128.","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Momozane, T., Inoue, M., Shintani, Y., Funaki, S., Kawamura, T., Minami, M., Shirakawa, Y., Kuratani, T., Sawa, Y. &amp; Okumura, M. (2016) Trimodality Therapy for an Advanced Thymic Carcinoma With Both Aorta and Vena Cava Invasion. <i>Ann. Thorac. Surg.<\/i>, 102, e139-e141.","DOI":"10.1016\/j.athoracsur.2016.01.014"},{"key":"25","unstructured":"Ninomiya, T., Yamagami, W., Susumu, N., Makabe, T., Sakai, K., Wada, M., Takigawa, A., Chiyoda, T., Nomura, H., Kataoka, F., Hirasawa, A., Banno, K. &amp; Aoki, D. (2016) Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer. <i>Anticancer Res.<\/i>, 36, 1751-1758."},{"key":"26","doi-asserted-by":"crossref","unstructured":"Oguri, T., Achiwa, H., Kato, D., Maeda, H., Niimi, T., Sato, S. &amp; Ueda, R. (2004) Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. <i>Chemotherapy<\/i>, 50, 279-282.","DOI":"10.1159\/000082626"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Ohe, Y., Niho, S., Kakinuma, R., Kubota, K., Ohmatsu, H., Goto, K., Nokihara, H., Kunitoh, H., Saijo, N., Aono, H., Watanabe, K., Tango, M., Yokohama, A. &amp; Nishiwaki, Y. (2004) A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. <i>Ann. Oncol.<\/i>, 15, 45-50.","DOI":"10.1093\/annonc\/mdh015"},{"key":"28","unstructured":"Osserman, K.E. &amp; Genkins, G. (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. <i>Mt. Sinai. J. Med.<\/i>, 38, 497-537."},{"key":"29","doi-asserted-by":"crossref","unstructured":"Park, S., Ahn, M.J., Ahn, J.S., Sun, J.M., Shim, Y.M., Kim, J., Choi, Y.S., Kim, K., Shin, S., Ahn, Y., Kwon, O.J., Kim, H., Lee, S.J., Chang, W.J. &amp; Park, K. (2013) A prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors. <i>J. Thorac. Oncol.<\/i>, 8, 959-966.","DOI":"10.1097\/JTO.0b013e318292c41e"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Ridwelski, K., Gebauer, T., Fahlke, J., Kr\u00f6ning, H., Kettner, E., Meyer, F., Eichelmann, K. &amp; Lippert, H. (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. <i>Ann. Oncol.<\/i>, 12, 47-51.","DOI":"10.1023\/A:1008328501128"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Roka, S., Kornek, G., Sch\u00fcller, J., Ortmann, E., Feichtinger, J. &amp; Armbruster, C. (2004) Carcinoma showing thymic-like elements: a rare malignancy of the thyroid gland. <i>Br. J. Surg.<\/i>, 91, 142-145.","DOI":"10.1002\/bjs.4510"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Romi, F. (2011) Thymoma in myasthenia gravis: from diagnosis to treatment. <i>Autoimmune Dis.<\/i>, 2011, doi:10.4061\/2011\/474512.","DOI":"10.4061\/2011\/474512"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Rosai, J. &amp; Sobin, L. (1999) World Health Organization International histological classification of tumors: <i>histological typing of tumors of the thymus<\/i>, Springer-Verlag, Berlin, Heidelberg.","DOI":"10.1007\/978-3-642-60157-6"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Shintani, Y., Ohta, M., Hazama, K., Miyoshi, S., Kagisaki, K. &amp; Matsuda, H. (2001) Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy. <i>Jpn. J. Thorac. Cardiovasc. Surg.<\/i>, 49, 717-721.","DOI":"10.1007\/BF02913512"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Simonelli, M., Zucali, P.A., Suter, M.B., Lorenzi, E., Rubino, L., Fatuzzo, G., Alloisio, M. &amp; Santoro, A. (2015) Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports. <i>Future Oncol.<\/i>, 11, 1223-1232.","DOI":"10.2217\/fon.14.318"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Venuta, F., Rendina, E.A., Longo, F., De Giacomo, T., Anile, M., Mercadante, E., Ventura, L., Osti, M.F., Francioni, F. &amp; Coloni, G.F. (2003) Long-term outcome after multimodality treatment for stage III thymic tumors. <i>Ann. Thorac. Surg.<\/i>, 76, 1866-1872.","DOI":"10.1016\/S0003-4975(03)01020-8"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Watanabe, N., Umemura, S., Niho, S., Kirita, K., Matsumoto, S., Yoh, K., Ohmatsu, H. &amp; Goto, K. (2015) Docetaxel for platinum-refractory advanced thymic carcinoma. <i>Jpn. J. Clin. Oncol.<\/i>, 45, 665-669.","DOI":"10.1093\/jjco\/hyv046"},{"key":"38","unstructured":"World Health Organization (1979) <i>WHO handbook for reporting results of cancer treatment<\/i>, World Health Organization, Geneva."},{"key":"39","doi-asserted-by":"crossref","unstructured":"Yu, L., Zhang, X.J., Ma, S., Li, F. &amp; Zhang, Y.F. (2012) Thoracoscopic thymectomy for myasthenia gravis with and without thymoma: a single-center experience. <i>Ann. Thorac. Surg.<\/i>, 93, 240-244.","DOI":"10.1016\/j.athoracsur.2011.04.043"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/241\/4\/241_281\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T14:18:24Z","timestamp":1498400304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/241\/4\/241_281\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.241.281","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}